Sa'ar Minha

Interventional cardiologist / Cardiologist
Assaf HaRofeh Medical Center - Beer Yaakov, Israel

Latest contributions

LAA closure and pulmonary embolism hotline

22 May 2026 – From EuroPCR 2026

Focusing on left atrial appendage (LAA) closure and pulmonary embolism management, this session reviews device-related thrombus, implant healing with novel coatings, and compares mechanical thrombectomy to catheter-directed thrombolysis. It also discusses the prognostic impact of hemodynamic data post-thrombectomy to inform clinical outcomes.

DCB - Going beyond in-stent restenosis

20 May 2026 – From EuroPCR 2026

This session examines the expanding role of drug-coated balloons (DCB) beyond in-stent restenosis, including treatment of acute coronary syndromes, calcified lesions, and bifurcations. It reviews current evidence supporting DCB-based revascularization and outlines essential procedural steps to optimize outcomes.

Imaging guidance in everyday practice

20 May 2026 – From EuroPCR 2026

This session emphasizes the role of imaging guidance in everyday interventional cardiology practice. Through challenging cases involving exertional chest pain, unusual coronary anatomy, complex left ventricular access, side branch navigation, and IVUS-guided re-intervention, it underscores the critical value of advanced imaging for diagnostic clarity and procedural...

Catheter-directed therapy for intermediate-high-risk and high-risk pulmonary embolism; where do we stand?

22 May 2025 – From EuroPCR 2025

Explore the evolving landscape of catheter-directed therapy for intermediate-high and high-risk pulmonary embolism. This session covers patient selection criteria, clinical signs indicating the need for intervention, management of potential complications, and ongoing studies shaping future treatments. Case-based discussions illustrate practical applications and key learnings.

Catheter-directed therapy for intermediate-high-risk and high-risk pulmonary embolism; where do we stand?

DCB after REC-CAGEFREE 1 - Vulnerable plaque PCI after PREVENT

21 May 2025 – From EuroPCR 2025

Reflect on the impact of recent trials REC-CAGEFREE 1 and PREVENT on the use of drug-coated balloons (DCB) and preventive PCI for vulnerable plaque. This session includes case discussions highlighting DCB applications and insights from cutting-edge clinical studies.

DCB after REC-CAGEFREE 1 - Vulnerable plaque PCI after PREVENT

Bifurcation lesions, challenges, failures and successes

15 May 2024 – From EuroPCR 2024

Bifurcation lesions, challenges, failures and successes